logo
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery

ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery

Business Wire19-06-2025
SAN CARLOS, Calif.--(BUSINESS WIRE)--ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region.
In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM).
Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities.
'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.'
The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system.
'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.'
As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day.
The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function.
ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes.
For more information about ZAP Surgical and the ZAP-X system, visit www.zapsurgical.com.
About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Life Sciences BC's 10th Annual Invest in BC Conference Connects Industry Leaders
Life Sciences BC's 10th Annual Invest in BC Conference Connects Industry Leaders

Business Wire

time4 minutes ago

  • Business Wire

Life Sciences BC's 10th Annual Invest in BC Conference Connects Industry Leaders

VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences British Columbia (LSBC) is proud to present the 10th Annual Invest in BC, powered by Lumira Ventures, taking place October 28–29, 2025 at the Vancouver Convention Centre West. Celebrating a decade of impact, Invest in BC has become a cornerstone event for the province's thriving life sciences sector. It brings together investors, entrepreneurs, researchers, and industry leaders for two days of high-impact networking, strategic partnering, and investment exploration. Whether attending to pitch, partner, or learn, participants will find unparalleled opportunities to connect and collaborate. 'Invest in BC is where innovation meets opportunity,' said Wendy Hurlburt, President and CEO of Life Sciences BC. 'This event brings together the full spectrum of our ecosystem—from early-stage ventures to global industry leaders—to spark conversations, build relationships, and accelerate the future of health.' Event Highlights: 30+ companies pitching across Biotech, MedTech, and Digital Health Dedicated partnering sessions for one-on-one meetings Exhibitor booths showcasing cutting-edge industry solutions Panels featuring ecosystem thought leaders Networking to spark meaningful connections Companies Selected to Pitch Include: Arbutus Medical, ARC Medical, AVEE HEALTH, Bold Therapeutics, Careteam Technologies, eSense Health, Evolved Therapeutics, Eyam Health, EyecareX, GuideStar Medical Devices, HTuO Biosciences, Ikomed, ImageCyte Technologies, Integrated Nanotherapeutics, Kapoose Creek Bio, Molecular You, NZ Technologies, Optigo Biotherapeutics, Pramana Pharmaceuticals, Redwood AI, Reverb Therapeutics, Seragene Therapeutics, Sonic Incytes, Sonus Microsystems, Sustained Therapeutics, Total Flow Medical, Variational AI, Vesalius Cardiovascular, ViewsML Technologies, VoxCell BioInnovation, and Zymeworks. "British Columbia's world-leading life sciences and biomanufacturing ecosystem continues to thrive, with B.C. companies making lives better globally," said Ravi Kahlon, Minister of Jobs and Economic Growth. "As uncertainty and anti-science sentiment grow south of our borders, B.C. remains a stable, science-driven jurisdiction committed to life sciences research and commercialization. We're making it easier than ever for companies to do business in the province. I invite investors and entrepreneurs to join the momentum and grow their businesses in B.C." Thank You to Our Confirmed Supporters Invest in BC is made possible by the generous support of these organizations: Event Details: Dates Location: Vancouver Convention Centre West Secure Your Spot: Early registration available until September 26. For more information or to register, visit:

The Beachbody Company, Inc. Announces Transfer of Stock Exchange Listing to Nasdaq
The Beachbody Company, Inc. Announces Transfer of Stock Exchange Listing to Nasdaq

Business Wire

time4 minutes ago

  • Business Wire

The Beachbody Company, Inc. Announces Transfer of Stock Exchange Listing to Nasdaq

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The Beachbody Company, Inc. (NYSE: BODi) (the 'Company') today announced that it will voluntarily transfer the listing of its Class A common stock to the Nasdaq Capital Market from the New York Stock Exchange ('NYSE'). The Company expects to begin trading as a Nasdaq-listed company on September 3, 2025. Following the transfer to Nasdaq, the Company's common stock will continue to trade under the symbol 'BODI'. 'Our move to Nasdaq will allow us to leverage their advanced trading technology and market data services to better serve our shareholders. As we continue to successfully execute against our strategic transformation, we're excited to join a community of the world's most dynamic companies on an exchange that shares our commitment to innovation,' commented Carl Daikeler, BODi's co-founder and Chief Executive Officer. 'Nasdaq has established itself as the premier destination for innovative game-changers that are reshaping their industries, disrupting traditional business models and creating new market opportunities. This move aligns BODi with a marketplace that values and supports transformative companies like ours,' said Mark Goldston, Executive Chairman of BODi. About BODi and The Beachbody Company, Inc. Originally known as Beachbody, BODi has been innovating structured step-by-step home fitness and nutrition programs for 25 years such as P90X, Insanity, and 21-Day Fix, plus the first premium superfood nutrition supplement, Shakeology. Since its inception in 1999 BODi has helped over 30 million customers pursue extraordinary life-changing results. The BODi community represents millions of people helping each other stay accountable to goals of healthy weight loss, improved strength and energy, and resilient mental and physical well-being. For more information, please visit Forward-Looking Statements This press release of The Beachbody Company, Inc. ('we,' 'us,' 'our,' and similar terms) contains 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are statements other than statements of historical facts and statements in future tense, including statements regarding the commencement of trading of our Class A common stock on the Nasdaq Capital Market. Forward-looking statements are based upon various estimates and assumptions, as well as information known to us as of the date hereof, and are subject to risks and uncertainties. Accordingly, actual results could differ materially due to a variety of factors, including: our ability to effectively compete in the fitness and nutrition industries; our ability to successfully acquire and integrate new operations; our reliance on a few key products; market conditions and global and economic factors beyond our control; intense competition and competitive pressures from other companies worldwide in the industries in which we operate; litigation and the ability to adequately protect our intellectual property rights; and the successful transfer of the listing of our Class A common stock on the Nasdaq. You can identify these statements by the use of terminology such as 'believe', 'plans', 'expect', 'will', 'should,' 'could', 'estimate', 'anticipate' or similar forward-looking terms. You should not rely on these forward-looking statements as they involve risks and uncertainties that may cause actual results to vary materially from the forward-looking statements. For more information regarding the risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, as well as risks relating to our business in general, we refer you to the 'Risk Factors' section of our Securities and Exchange Commission filings, including those risks and uncertainties included in the Form 10-K filed with the SEC on March 28, 2025 and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, which are available on the Investor Relations page of our website at and on the SEC website at All forward-looking statements contained herein are based on information available to us as of the date hereof and you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. We undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations, except as required by law. Undue reliance should not be placed on forward-looking statements.

Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer

Business Wire

time4 minutes ago

  • Business Wire

Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store